Back to search

Article

Iguratimod Attenuates Diabetic Cognitive Impairment via Suppressing B Cell Activation and CD8+ T Cell Cytotoxicity

2025-06-27

Abstract excerpt

<h4>Background: </h4> and Purpose Diabetes-induced cognitive impairment (DCI) is a common complication in diabetic patients with an unclear pathogenesis, and there are currently no approved therapeutic drugs available. Iguratimod (IGU) is a novel small molecule immunosuppressant used to treat rheumatoid arthritis. Given the emerging evidence revealing that immune responses mediate cognitive impairment, our study i...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d8c0fd60-a429-5d51-bb8e-aa75cf00e610
DOI
10.22541/au.175102422.26432301/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Iguratimod Attenuates Diabetic Cognitive Impairment via Suppressing B Cell Activation and CD8+ T Cell CytotoxicityDOI 10.22541/au.175102422.26432301/v1
Select a neighboring publication to make it the new centre.